Standout Papers

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease 2009 2026 2014 2020 1.4k
  1. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease (2009)
    Marc A. Pfeffer, Emmanuel A. Burdmann et al. New England Journal of Medicine

Immediate Impact

6 by Nobel laureates 5 from Science/Nature 62 standout
Sub-graph 1 of 22

Citing Papers

Frailty in Older Adults
2024 Standout
Empagliflozin in Patients with Chronic Kidney Disease
2022 Standout
2 intermediate papers

Works of Reshma Kewalramani being referenced

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
2016
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout

Author Peers

Author Last Decade Papers Cites
Reshma Kewalramani 1355 1271 477 28 2.5k
Dimitrios Tsakiris 1137 1343 448 21 2.3k
Peter Ivanovich 1476 1695 605 75 3.3k
Jan Feyzi 734 1059 391 15 2.4k
Steven Fishbane 1028 1421 741 70 2.4k
Lloyd S. Ibels 1609 630 206 36 2.5k
Bradley J. Maroni 1943 922 176 40 3.0k
G Mecca 1364 863 320 59 3.3k
Hans Henrik Parving 1181 1079 416 12 2.8k
Dov Wexler 605 1514 423 39 2.5k
Kezhen L. Tang 979 1709 651 18 4.9k

All Works

Loading papers...

Rankless by CCL
2026